Survival Benefit of Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer: A Multi-institutional Case Control Study
- 13 May 2014
- journal article
- research article
- Published by Springer Nature in Annals of Surgical Oncology
- Vol. 21 (11) , 3621-3627
Abstract
Hyperthermic intraperitoneal chemotherapy (HIPEC) and complete surgical removal of the tumor, in relapsing patients may provide a clinical benefit. There is no consensus considering the place of HIPEC for patients who had first ovarian cancer relapse. To assess for possible efficacy of HIPEC on overall survival (OS) rates in this situation, we performed a multi-institutional study. The current study was a retrospective case control multi-institutional study comparing a group of patients treated with HIPEC to a group of patients treated without HIPEC. Inclusion criteria were first relapse of a serous ovarian carcinoma and >6 months after the end of initial treatment. Exclusion criteria were another pathological subtype of ovarian cancer, a relapse at p = 0.013). In a multivariate analysis, HIPEC and interval-free before the end of initial treatment were both independent prognostic factors. When compared to the control group, complete secondary surgery and HIPEC appear to afford a better OS rate than complete secondary surgery alone, in case of first ovarian cancer relapse. Further randomized trials are warranted to confirm these results.Keywords
This publication has 27 references indexed in Scilit:
- Current Status and Future Directions of Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy in the Treatment of Ovarian CancerSurgical Oncology Clinics of North America, 2012
- Intraperitoneal Chemotherapy for Recurrent Epithelial Ovarian Cancer Is Feasible With High Completion Rates, Low Complications, and Acceptable Patient OutcomesInternational Journal of Gynecological Cancer, 2012
- Prognostic factors for patients treated for a recurrent FIGO stage III ovarian cancer: A retrospective study of 108 casesEuropean Journal of Surgical Oncology, 2011
- The impact of PET-CT in suspected recurrent ovarian cancer: A prospective multi-centre study as part of the Australian PET Data Collection ProjectGynecologic Oncology, 2009
- La fréquence des cancers en France en 2006 et les évolutions de la mortalité depuis 1950 et de l’incidence depuis 1980Bulletin du Cancer, 2009
- Cytoreductive surgery for recurrent ovarian cancer: A meta-analysisGynecologic Oncology, 2009
- Surgery in Recurrent Ovarian Cancer: The Arbeitsgemeinschaft Gynaekologische Onkologie (AGO) DESKTOP OVAR TrialAnnals of Surgical Oncology, 2006
- Intraperitoneal Cisplatin and Paclitaxel in Ovarian CancerNew England Journal of Medicine, 2006
- Tertiary cytoreduction in patients with recurrent ovarian carcinomaGynecologic Oncology, 2004
- Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO-OVAR-2.2 trialThe Lancet, 2003